About
Iscaffpharma’s mission is to establish the scaffold technology as a gold standard for cancer drug development. We also aim to develop own successful treatments for aggressive cancer using our proprietary technology with human and synthetic scaffolds that mimic true human cancer microenvironment. The over-all result being increased success rate in clinical development of cancer drugs.
Vision & Mission
Cancer remains a major health issue through-out the world and rates are increasing.
Despite the progress that has been made there is a high unmet need to cure aggressive forms of cancer. Our vision is to cure cancer by generating precision medicin
Our mission is to establish the scaffold technology as gold standard for cancer drug development and develop own successful treatments for aggressive cancer.
About ISCAFFPHARMA
Iscaffpharma is a Bio-Tech company founded in Gothenburg, Sweden, focusing on developing better treatments for aggressive cancers. The development is based on research by professor Göran Landberg and professor Anders Ståhlberg at Sahlgrenska Cancer Center. The research has shown that the scaffold (environment) of the tumour impacts the aggressiveness of cancers. Iscaffpharma has developed this technology into a robust and effecient platform to improve success rate in clinical development of treatments for aggressive cancer.
We provide patient derived and synthetic scaffolds mimicking the human tumour microenvironment as a tool and platform for research and development. The 3D scaffolds can predict the efficacy of drug treatment and provide high quality data to support decision on which drugs to move into clinical programs.
Substantial R&D funding has been received by Iscaffpharma being part in Vinnova grant (45 million Skr) – challenge driven innovation (UDI 3), Eurostar project with a total budget of 12 MSEK. Initial collaboration agreements with cancer drug developing companies have been established. The research has generated an approved patent and additional patent applications are filed.
In the research groups of Göran Landberg and Anders Ståhlberg more than 25 Phd’s are employed.
Board of directors
Lorna Fletcher – Chairman of the board
More info to come.
Sara Malcus – Chairman of the board
Sara Malcus has more than 15 years of experience from the pharmaceutical and biotech industries. She is the former CEO and co-founder of MetaboGen, a microbiome company (acquired by BioGaia) and has served on the boards of Vicore Pharma and Oncorena. Sara has a PhD in Inflammation Medicine and extensive experience in the management of small companies in the life science sector, from positions in business development and investment management, both at Astra Zeneca and GU Ventures.
Göran Landberg – Board Member & CSO
Founder of Iscaff Pharma, Professor and senior consultant in pathology and the principal investigator of a large research group at the Sahlgrenska Cancer Center at the University of Gothenburg. His research interest is focused on molecular pathology based translational projects with a goal to develop novel diagnostic and treatment principles for cancer patients better targeting true malignant features by understanding key tumour biological issues and properties including the tumour microenvironment.
Göran Landberg – CMO
Founder of Iscaff Pharma, Professor and senior consultant in pathology and the principal investigator of a large research group at the Sahlgrenska Cancer Center at the University of Gothenburg. His research interest is focused on molecular pathology based translational projects with a goal to develop novel diagnostic and treatment principles for cancer patients better targeting true malignant features by understanding key tumour biological issues and properties including the tumour microenvironment.
Partners and Collaborators
Iscaffpharma is part of UDI3 challenge driven innovation supported by Vinnova. Our partners are:
